Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy

AIDS

Volumn 19, Issue 15, 2005, Pages 1700-1702

  Petersen, Kyle ^a   Riddle, Mark S ^b   Jones, Lindsay E ^a   Furtek, Kari J ^c   Christensen, Anne R ^c   Tasker, Sybil A ^a   Hale, Braden R ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b US Naval Medical Research Unit No 3 Egypt   (Egypt)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BILIRUBIN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLASSIFICATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

EID: 27144518127     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000186826.60983.85     Document Type: Article

References (9)

1. Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, Wagener MM. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999; 29:824-830.
2. Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, Anton P, Gonzalez-Lahoz J. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998; 12:1112-1113.
3. Hugen PW, Langebeek N, Burger DM, Zomer B, van Leusen R, Schuurman R, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 2002; 30:324-334.
4. Duong M, Piroth L, Peytavin G, Forte F, Kohli E, Grappin M, et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis 2001; 33:386-392.
5. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection 2004. Recommendations of the International AIDS Society - USA Panel JAMA 2004; 292:251-265.
6. Barrios A, Rendon AL, Gallego O, Martin-Carbonero L, Valer L, Rios P, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004; 5:201-205.
7. O'Mara EM, Mummaneni V, Randall D, Burchell B, Baty D, Tanner T, et al. Assessment of the effect of uridine diphosphate glucuronosyltransferase (UDP-GT) 1A1 genotype on indirect bilirubin elevations in healthy subjects dosed with BMS-232632. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000 [Abstract no. 180].
8. Martinez E, Azuaje CJ, Serrano O, Rivero A, Lozano F, Deig E, et al. Effects of switching to ritonavir boosted atazanavir (ATV) on HIV-infected patients receiving antiretroviral therapy with hyperlipidemia. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA, February 2005 [Abstract no. 850].
9. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671-12676.